Join our research study “ Alpha linolenic acid (ALA) for the prevention of cognitive decline in APOE4 older adults with mild cognitive impairment”
Are you 60 years of age or older, with a diagnosis of amnestic MCI? You might be eligible to participate in our trial of ALA for the prevention of cognitive decline!
We aim to determine the effects of ALA on cognitive and brain health in an at-risk population We are looking for individuals aged 60 and older, with a diagnosis of amnestic MCI. This study will evaluate the effects of alpha-linolenic acid (ALA) supplementation on cognitive function and brain health in older adults with mild cognitive impairment and APOE4 genotype (a risk factor for Alzheimer’s Disease).
All research participants will complete a screening visit, during which they will complete a medical assessment, cognitive screening, and a blood draw. Participants will receive genetic testing for the APOE4 genotype (a risk factor for Alzheimer’s disease). This will determine whether an individual is eligible.
Those with the APOE4 genotype will be eligible for a clinical trial of Alpha linolenic acid (ALA), a safe, potentially therapeutic strategy for older adults at risk for Alzheimer’s disease. Participants will receive either daily supplementation of ALA or a placebo for six months, and will complete several visits over those six months.
Visits will include cognitive testing, MRI scanning, a blood draw, and other measures of sleep, diet, and functioning. As this is a clinical trial, participants may potentially benefit if our hypothesis that ALA improves brain function and cognition is confirmed.
Participants will receive up to a total of $300 and will be reimbursed for travel.
For eligibility and inquiries, contact us at adrd@bhi.rutgers.edu.
Investigator: Michal Schnaider Beeri